Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

ia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept submitted an NDA to the FDA via the 505(b)(2) pathway on September 30, 2008.

For further information, please visit the company's website at: http://www.transcept.com.

About Novacea

Novacea, Inc. is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including Asentar(TM), which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of closing the merger, the expected cash balance of the combined entity as of the closing, the sufficiency of post closing cash to fund development of Intermezzo(R) through planned commercialization and the potential markets and expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the clos
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc ... the Company has received a complete response letter ... for its New Drug Application (NDA) for the ... the treatment of hypertension.   Photo - ... are disappointed in the receipt of a complete ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... N.Y., May 2, 2011 Henry Schein, Inc., (NASDAQ: ... and services to office-based practitioners, announced today that ... Schein, and Steven Paladino, the Company,s Executive Vice President and ... Annual Health Care Conference on May 4, 2011. The conference ...
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... first quarter of 2011.  First quarter revenue increased to ... same period of 2010.  This increase was principally driven ... and license revenues.  Cambridge Research & Instrumentation, Inc. ("CRi"), ...
Cached Medicine Technology:Henry Schein to Present at Deutsche Bank 36th Annual Health Care Conference 2Caliper Life Sciences Reports First Quarter 2011 Results 2Caliper Life Sciences Reports First Quarter 2011 Results 3Caliper Life Sciences Reports First Quarter 2011 Results 4Caliper Life Sciences Reports First Quarter 2011 Results 5Caliper Life Sciences Reports First Quarter 2011 Results 6Caliper Life Sciences Reports First Quarter 2011 Results 7Caliper Life Sciences Reports First Quarter 2011 Results 8Caliper Life Sciences Reports First Quarter 2011 Results 9Caliper Life Sciences Reports First Quarter 2011 Results 10
(Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
(Date:12/26/2014)... “Many people become overwhelmed by the thought ... and phone calls with insurance companies,” The Jones Firm ... free eBook on pedestrian and bicycle accidents . ... bicycle auto accident claims assures the injured individual that ... handling their case while they focus on recovering. ...
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding ... new selection of black one-shoulder cocktail dresses . In ... are available at discounted prices, up to 70% off. ... for three weeks only. You know, we have thousands of ... in our new items can visit our website for more ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... MONDAY, Oct. 31 (HealthDay News) -- Certain factors unique to ... contagious norovirus among teams and their staff, a new report ... (often referred to as stomach flu) and causes 21 million ... The report, published in the Oct. 31 online edition of ...
... Just two extra hours of focused training significantly increased ... polyps , known as adenomas, in the colon, according ... These findings suggest that new methods to educate endoscopists, ... colorectal cancer detection rates and potentially reduce cancer ...
... new study describes a 2010 outbreak involving several ... norovirus outbreak in a professional sports association. Published ... online ( http://www.oxfordjournals.org/our_journals/cid/prpaper.pdf ), the study highlights unique ... players and staff on and off the court. ...
... birth control are vastly different from those used by ... hormones and with different means of delivery (not just ... to women,s pleasure remain. An Indiana University ... affect things such as arousal, lubrication and orgasm, found ...
... PHILADELPHIA, PA (October 30 2011)In a technical tour de ... and cross-indexed the actions of 178 candidate drugs capable ... 300 enzymes, including enzymes critical for cancer and other ... been made available online to the research community. This ...
... addicts to repeatedly choose drugs, alcohol, cigarettes, overeating, ... Neuroscientists at the University of California, Berkeley, ... where calculations are made that can result in ... have found how neural activity in the brain,s ...
Cached Medicine News:Health News:Stomach Bug Easily Passed Among Pro Sports Teams: Report 2Health News:Mayo Clinic: Short training course significantly improves detection of precancerous polyps 2Health News:Mayo Clinic: Short training course significantly improves detection of precancerous polyps 3Health News:NBA players not immune to serious illness from norovirus 2Health News:Not your mother's birth control, same troubles 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 3Health News:UC Berkeley findings offer new clues into the addicted brain 2Health News:UC Berkeley findings offer new clues into the addicted brain 3
3.2 mm Keratome, double bevel, sharp sides, ang. 1 Ea as quantity....
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles....
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Lorgnette pinhole occluder...
Medicine Products: